NCT04790032Completed
Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)
PharmacOdynaMic Effects of Cangrelor in PatiEnts wIth Acute or chronIc Coronary Syndrome Undergoing Percutaneous Coronary Intervention (POMPEII Registry)
Source: ClinicalTrials.gov · Last updated 7 Aug 2025
Brief summary (registry, in English)
This prospective registry was designed to carefully investigate the pharmacodynamic (PD) effects of cangrelor in all patients undergoing percutaneous coronary intervention (PCI).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 4 Mar 2021
- Start date
- 16 Mar 2021
- Primary completion date
- 1 Jul 2024
- Lead sponsor
- Federico II University
- Diseases
- Coronary artery disease
- NCT number
- NCT04790032
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 16 Mar 2021 to the primary completion date, 1 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- only those not providing consent to blood/data collection will be excluded.
Who the study is looking for
- All adult patients undergoing PCI and receiving cangrelor administration will be eligible for inclusion in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Federico II of Naples Coordinator of this site? Confirm its status | Naples | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.